Arena Capital Advisors’s Orion Biotech Opportunities Corp. Class A Ordinary Share ORIA Stock Holding History

Arena Capital Advisors’s Portfolio ORIA Stock Details ORIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-141,317	Closed	-$1.45M	–	101
2023 Q1	$1.45M	Hold	141,317	–	–	2.02%	13
2022 Q4	$1.42M	Hold	141,317	–	–	0.78%	38
2022 Q3	$1.39M	Sell	141,317 -109,600	-44%	-$1.08M	0.42%	63
2022 Q2	$2.44M	Sell	250,917 -252,917	-50%	-$2.47M	0.62%	59
2022 Q1	$4.91M	Sell	503,834 -96,166	-16%	-$933K	0.75%	45
2021 Q4	$5.85M	Hold	600,000	–	–	0.54%	63
2021 Q3	$5.87M	Buy	+600,000	New	+$5.86M	0.46%	71

Arena Capital Advisors's ORIA Position: Q2 2023 in Review

Arena Capital Advisors sold out of Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) in Q2 2023, closing a stake of 141,317 shares — an estimated $1.45M sold.

Arena Capital Advisors first reported a position in ORIA in Q3 2021 and held it in 7 quarters. The position peaked at $5.87M in Q3 2021. 0 funds tracked by Wall St. Rank hold ORIA as of Q2 2023.

Arena Capital Advisors reported no remaining Orion Biotech Opportunities Corp. Class A Ordinary Share position as of Q2 2023 after selling out during the quarter.
Arena Capital Advisors sold 141,317 Orion Biotech Opportunities Corp. Class A Ordinary Share shares in Q2 2023, an estimated $1.45M.
Arena Capital Advisors first reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share in Q3 2021 and held it in 7 quarters.
Arena Capital Advisors's Orion Biotech Opportunities Corp. Class A Ordinary Share position peaked at $5.87M in Q3 2021.
0 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Class A Ordinary Share as of Q2 2023.

Based on Arena Capital Advisors's 13F filing for Q2 2023, filed 1 Aug 2023.